Wet AMD

EyePoint (EYPT) is undertaking a public offering to raise $150 million, priced on October 14, 2025. The offering includes 11,000,000 shares at $12.00 each and warrants for 1,500,000 shares at $11.999 each. Expected closing is around October 16, 2025. Underwriters have the option to purchase 1,875,000 more shares. Net proceeds will fund DURAVYU’s clinical development for wet AMD and DME, other pipeline projects, and general corporate expenses. The offering will be dilutive if warrants and the underwriter option are fully exercised.